juillet 26, 2010
Aurgalys launches new offer for public companies: investor relation and equity research
Paris, July 5th, 2011 – Aurgalys, a global provider for life sciences and healthcare companies through corporate finance, business development and interim management services, is pleased to announce today the launch of new services for public companies, investor relations and equity research.
Download our July 7th, 2012 presse release here (available in english only)
juin 22, 2010
Paris, Tel-Aviv, Lausanne, Buenos Aires, June 22, 2010 – Aurgalys, a global provider for life sciences companies through corporate finance, business development and interim management services, is pleased to announce today the appointment of Dr Lila Drittanti as Aurgalys partner and the opening of Latin America offices.
Download our press release here ( english)
Télécharger notre communiqué de presse ici (français)
avril 07, 2010
Aurgalys issued today April 7th, 2010, an new analyst report on BioAlliance.
Since our coverage initiated on June 19th, 2009, the stock increased 69% from €3.44 to €5.81 today.
Given the recent Company newsflow with the approval of Setofilm in Europe, the approval of Loramyc in 13 new European countries, making it 26, the new partner Therabel for the commercialization of Loramyc and Setofilm in Europe, using a risk-adjusted NPV method, we confirm our BUY recommendation and we give a target price of €13.3 within 12 months. This value will bring the market capitalization to €171.5 compared to €74.9 M as of today.
Download our BioAlliance Analyst Report here (available in english only)
www.bioalliancepharma.com
janvier 22, 2010
Through our analysis we considered that for BioAlliance:
- Major milestones were met in 2009
- Two products are due to be launched in new markets
- Five products currently in clinical development including one which has completed phase III
We recommand a BUY for the stocks with a target price of €12 within one year
Download our BioAlliance Coverage here (available in english only)
www.bioalliancepharma.com
décembre 15, 2009
December 15th, 2009, Aurgalys and Cukierman & Co Life Sciences Cukierman & Co. Life Sciences annouces that they have successfully advised Swiss company Evolva [SIX: EVE] in a CHF21M financial round
Download our English Press Release here
août 31, 2009
Considering the following key points:
Acyclovir Lauriad® positive phase III results
Loramyc® sales increase for first half 2009
We observe that shares remain undervalued, thus we reiterate a BUY
recommendation
Download our BioAlliance Coverage here (available in english only)
www.bioalliancepharma.com
juin 19, 2009
BioAlliance Pharma is a biopharmaceutical company which develops and markets innovative therapeutics addressing unmet medical needs in the treatment and supportive care of life threatening diseases including cancer and AIDS
Download our BioAlliance Coverage here (available in english only)
www.bioalliancepharma.com
janvier 06, 2009
Aurgalys and Cukierman & Co Life Sciences sign a business affiliate agreement to offer global solutions to the life science industry in Europe, North America and Israel. Given the current global financial crisis and new market needs, the partners’ core service offering focuses on M&A activity and strategic alliances
Download our English Press Release here
Téléchargez notre communiqué de presse, en français en cliquant ici